• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在高风险成年人中，第二剂接种后≥14 天， Moderna 疫苗对 COVID-19 的有效性为 94%。

In high-risk adults, the Moderna vaccine had 94% efficacy against COVID-19 ≥14 d after the 2nd dose.

机构信息

McMaster University, Hamilton, Ontario, Canada (Z.C.).

出版信息

Ann Intern Med. 2021 Mar;174(3):JC28. doi: 10.7326/ACPJ202103160-028. Epub 2021 Mar 2.

DOI:10.7326/ACPJ202103160-028
PMID:33646836
Abstract

Baden LR, El Sahly HM, Essink B, et al. N Engl J Med. 2021;384:403-16. 33378609.

摘要

巴登 L.R.，埃尔萨利 H.M.，埃辛克 B.等人。《新英格兰医学杂志》.2021;384:403-16. 33378609.

相似文献

1
In high-risk adults, the Moderna vaccine had 94% efficacy against COVID-19 ≥14 d after the 2nd dose.在高风险成年人中，第二剂接种后≥14 天， Moderna 疫苗对 COVID-19 的有效性为 94%。
Ann Intern Med. 2021 Mar;174(3):JC28. doi: 10.7326/ACPJ202103160-028. Epub 2021 Mar 2.
2
The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose.BNT162b2（辉瑞/生物科技）疫苗在第 2 剂接种后 ≥7 天对 COVID-19 的有效率为 95%。
Ann Intern Med. 2021 Feb;174(2):JC15. doi: 10.7326/ACPJ202102160-015. Epub 2021 Feb 2.
3
The single-dose J&J vaccine had 67% efficacy against moderate to severe-critical COVID-19 at ≥14 d.单剂强生疫苗在 ≥14 天对中重度至重症 COVID-19 的有效性为 67%。
Ann Intern Med. 2021 Jul;174(7):JC75. doi: 10.7326/ACPJ202107200-075. Epub 2021 Jul 6.
4
COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.COVID-19 疫苗：辉瑞/生物科技和 Moderna 疫苗的生物学、药理学特征和不良反应比较。
Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669. doi: 10.26355/eurrev_202102_24877.
5
The Novavax vaccine had 90% efficacy against COVID-19 ≥7 d after the second dose.该诺瓦瓦克斯疫苗在第二剂接种后 7 天对 COVID-19 的有效性为 90%。
Ann Intern Med. 2021 Nov;174(11):JC124. doi: 10.7326/ACPJ202111160-124. Epub 2021 Nov 2.
6
In adults, the Oxford/AstraZeneca vaccine had 70% efficacy against COVID-19 >14 d after the 2nd dose.在成年人中，牛津/阿斯利康疫苗在第 2 剂接种后 14 天以上对 COVID-19 的有效率为 70%。
Ann Intern Med. 2021 Mar;174(3):JC29. doi: 10.7326/ACPJ202103160-029. Epub 2021 Mar 2.
7
In South Africa, a 2-dose Oxford/AZ vaccine did not prevent mild to moderate COVID-19 (cases mainly B.1.351 variant).在南非，两剂牛津/阿斯利康疫苗未能预防轻症至中症 COVID-19（病例主要为 B.1.351 变异株）。
Ann Intern Med. 2021 May;174(5):JC50. doi: 10.7326/ACPJ202105180-050. Epub 2021 May 4.
8
In adults who had not had COVID-19, Novavax vaccine had 90% efficacy at ≥7 d after the second dose.在未感染过 COVID-19 的成年人中，第二剂接种后≥7 天，Novavax 疫苗的有效性为 90%。
Ann Intern Med. 2022 May;175(5):JC52. doi: 10.7326/J22-0028. Epub 2022 May 3.
9
Trans-Amplifying RNA Vaccines Against Infectious Diseases: A Comparison with Non-Replicating and Self-Amplifying RNA.针对传染病的反式扩增RNA疫苗：与非复制型和自我扩增型RNA的比较
Methods Mol Biol. 2024;2786:135-144. doi: 10.1007/978-1-0716-3770-8_5.
10
COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) in patients with multiple sclerosis: a statement by a working group convened by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society.新型冠状病毒肺炎（COVID-19）mRNA 疫苗（辉瑞-生物科技和 Moderna）在多发性硬化症患者中的应用：波兰神经病学会多发性硬化症和神经免疫学分会召集的工作组的一份声明。
Neurol Neurochir Pol. 2021;55(1):8-11. doi: 10.5603/PJNNS.a2021.0016. Epub 2021 Feb 8.

引用本文的文献

1
Lessons we learned during the past four challenging years in the COVID-19 era: pharmacotherapy, long COVID complications, and vaccine development.我们在新冠疫情时代过去四年充满挑战的岁月中学到的经验教训：药物治疗、新冠长期并发症和疫苗研发。
Virol J. 2024 Apr 26;21(1):98. doi: 10.1186/s12985-024-02370-6.
2
Kinetics of adaptive immune responses after administering mRNA-Based COVID-19 vaccination in individuals with and without prior SARS-CoV-2 infections.mRNA 新冠疫苗接种对既往 SARS-CoV-2 感染者和未感染者适应性免疫应答动力学的影响。
BMC Infect Dis. 2023 Oct 27;23(1):732. doi: 10.1186/s12879-023-08728-5.
3
SARS-CoV-2 mRNA vaccination induces an intranasal mucosal response characterized by neutralizing antibodies.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）信使核糖核酸（mRNA）疫苗接种可诱导以中和抗体为特征的鼻内黏膜反应。
J Allergy Clin Immunol Glob. 2023 Jun 25;2(4):100129. doi: 10.1016/j.jacig.2023.100129. eCollection 2023 Nov.
4
Immune Thrombocytopenia Relapse in Patients Who Received mRNA COVID-19 Vaccines.接受mRNA新冠疫苗接种患者的免疫性血小板减少症复发
J Blood Med. 2023 Apr 14;14:295-302. doi: 10.2147/JBM.S396026. eCollection 2023.
5
Long COVID in the context of social determinants of health.长新冠在健康社会决定因素方面的问题。
Front Public Health. 2023 Mar 28;11:1098443. doi: 10.3389/fpubh.2023.1098443. eCollection 2023.
6
Reduction in COVID-19 Vaccine Effectiveness against SARS-CoV-2 Variants in Seoul according to Age, Sex, and Symptoms: A Test-Negative Case-Control Study.根据年龄、性别和症状，首尔地区 COVID-19 疫苗对 SARS-CoV-2 变异体有效性降低：一项病例对照研究。
Int J Environ Res Public Health. 2022 Dec 16;19(24):16958. doi: 10.3390/ijerph192416958.
7
Efficacy versus abundancy: Comparing vaccination schemes.功效与数量：比较疫苗接种方案。
PLoS One. 2022 May 12;17(5):e0267840. doi: 10.1371/journal.pone.0267840. eCollection 2022.
8
Chitosan Nanoparticles for Antiviral Drug Delivery: A Novel Route for COVID-19 Treatment.壳聚糖纳米粒作为抗病毒药物递送载体：COVID-19 治疗的新途径。
Int J Nanomedicine. 2021 Dec 16;16:8141-8158. doi: 10.2147/IJN.S332385. eCollection 2021.
9
Proposals to Accelerate Novel Vaccine Development for Children.加速儿童新型疫苗研发的建议。
Pediatrics. 2021 Oct 22;149(1). doi: 10.1542/peds.2021-054593.
10
A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines.聚焦于现有 COVID-19 疫苗的技术、机制、安全性和有效性的综述。
Int Immunopharmacol. 2021 Nov;100:108162. doi: 10.1016/j.intimp.2021.108162. Epub 2021 Sep 17.